Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Biotechnology & Medical Research

Delayed Australian S.E. 09:01:09 2024-07-22 pm EDT 5-day change 1st Jan Change
0.1675 AUD +1.52% Intraday chart for Arovella Therapeutics Limited +8.06% +45.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Arovella Therapeutics Limited announced a financing transaction CI
Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement MT
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9% MT
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4% MT
Arovella Therapeutics Ltd. Announces Change of Company Address CI
Arovella Therapeutics Appoints CFO MT
Arovella Therapeutics Limited Announces Changes to its Board CI
Arovella Therapeutics Limited Announces Executive Changes CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023 MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6% MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance MT
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan MT
Arovella Therapeutics Completes Closure of Perth R&D Facility MT
Arovella Therapeutics Appoints Nonexecutive Chair MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase MT
Chart Arovella Therapeutics Limited
More charts
Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALA Stock
  4. News Arovella Therapeutics Limited
  5. Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement